Hengrui Pharmaceutical
Founded in 1970, Hengrui Medicine is a national pharmaceutical enterprise engaged in the development and promotion of innovative and high-quality drugs. It has developed into a well-known domestic supplier of antitumor drugs, surgical drugs and imaging interventional products. In the 2021 TOP50 list of global pharmaceutical companies published by the American Pharmaceutical Managers Magazine, Hengrui has been on the list for three consecutive years, and the ranking has climbed to the 38th place year by year; No. 1 in the list of the best industrial companies for R&D product lines.
Hansoh Pharmaceutical
Established in 1995, Hansoh Pharma is a leading innovation-driven pharmaceutical company in China. Adhering to the corporate mission of "making national medicine better and strengthening China's creation", it is committed to improving human health through continuous innovation, focusing on anti-tumor, central Nervous system, anti-infection and diabetes and other major disease treatment areas. The company has been ranked among the top 30 of China's top 100 pharmaceutical industry companies and the top 3 of the best industrial enterprises in China's pharmaceutical R&D product line for many years. It is a national key high-tech enterprise and a national technology innovation demonstration enterprise. The company was listed on the Hong Kong Stock Exchange in June 2019 (HK.03692).
Kangyuan Pharmaceutical
Jiangsu Kangyuan Pharmaceutical Co., Ltd. is a large-scale traditional Chinese medicine enterprise integrating drug research and development, production and sales. The fifth place in the top ten, and the top 20 innovative pharmaceutical enterprises in China, with more than 5,000 employees. There are several national-level scientific research platforms such as the "State Key Laboratory of New Technology in Traditional Chinese Medicine Pharmaceutical Processes". In 2018, the laboratory was awarded the "State Key Laboratory of Excellent Enterprises" (the first in the pharmaceutical field). It has successively obtained 47 national-level new traditional Chinese medicines and 331 invention patents; undertaken more than 50 scientific and technological projects; won 1 second-class national technological invention award, 2 second-class national scientific and technological progress awards, and provincial and ministerial-level scientific and technological progress awards 8 (including 2 first prizes for scientific and technological progress in Jiangsu Province); R&D strength ranks first in the "Traditional Chinese Medicine R&D Strength Ranking" for three consecutive years. Guizhi Fuling Capsule has completed Phase II clinical trials in the United States, and is an international demonstration variety of Chinese medicine in my country.
Adhering to the historical mission of "revitalizing Chinese medicine and serving the motherland", the company has formed a cluster of "Chinese medicine, chemical medicine, biopharmaceuticals" as the main line of innovation and development in the course of decades of development. development system. Realize the simultaneous development of "quality improvement" and "scale expansion" of the big health industry, and comprehensively enhance the core competitiveness of enterprises.
CTTQ
CTTQ Pharmaceutical Group is an innovative pharmaceutical group engaged in the research, development, production and sales of pharmaceutical innovations and high-quality drugs. It is committed to providing patients with better health solutions and high-quality affordable medical resources. It is a well-known domestic The R&D and production base of anti-tumor and liver disease drugs is a national key high-tech enterprise and a key backbone enterprise of the Lianyungang New Pharmaceutical Industry Base of the National Torch Program. Best Industrial Enterprise in Product Line (selected and released by China Pharmaceutical Industry Information Center).
